Novavax COVID-19 Vaccine Nuvaxovid(TM) Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents

23-06-2022 21:08 | 4 dagen geleden Economie

Dit is een origineel bericht van
PR Newswire

-- Upon authorization, Nuvaxovid(TM) would be the first protein-based option for adolescents aged 12 through 17 in Europe -- Nuvaxovid(TM) demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 23, 2022 /PRNewswire/ -- Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Nuvaxovid(TM) (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) for adolescents aged 12 through 17. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from the Phase 3 PREVENT-19 clinical trial.

"This recommendation brings us closer to offering adolescents in the EU the first protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax.

The CHMP recommendation was based on data from the ongoing pediatric expansion of PREVENT-19, a pivotal Phase 3 trial of 2,247 adolescents aged 12 through 17 across 73 sites in the U.S., to evaluate the safety, effectiveness (immunogenicity), and efficacy of Nuvaxovid. In the trial, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the trial showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. Fever was seen more frequently in adolescents than in adults. These effects are usually mild or moderate and improve within a few days from the vaccination.

The European Commission (EC) granted CMA for Nuvaxovid to prevent COVID-19 in people 18 years of age and over in December 2021.

In the 12 through 17 year-old population, emergency use authorization has been granted in India.

The Novavax COVID-19 vaccine (NVX-CoV2373) has not yet been authorized for use in the U.S. and the trade name Nuvaxovid(TM) has not yet been approved by the U.S. Food and Drug Administration.

-- Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients. -- Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid. -- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting. -- Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination. -- Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals. -- The efficacy of Nuvaxovid may be lower in immunosuppressed individuals. -- Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus. -- The effects with Nuvaxovid may temporarily affect the ability to drive or use machines. -- Individuals may not be fully protected until seven days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients. -- The most common adverse reactions observed during clinical studies were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. For additional information on Nuvaxovid, please visit the following websites:

-- Novavax global authorization website [https://c212.net/c/link/?t=0&l=en&o=3576637-1&h=3664322855&u=https%3A%2 F%2Fwww.novavaxcovidvaccine.com%2F&a=global+authorization+website] -- European Medicines Agency [https://c212.net/c/link/?t=0&l=en&o=3576637-1&h=3113743083&u=https%3A%2 F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D154535 0530%26u%3Dhttps%253A%252F%252Fwww.ema.europa.eu%252Fen%252Fmedicines%25 2Fhuman%252FEPAR%252Fnuvaxovid%26a%3DEuropean%2BMedicines%2BAgency&a=Eur opean+Medicines+Agency] -- European Commission [https://c212.net/c/link/?t=0&l=en&o=3576637-1&h=628121259&u=https%3A%2F %2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3490095-1%26h%3D2784477 625%26u%3Dhttps%253A%252F%252Fec.europa.eu%252Fcommission%252Fpresscorne r%252Fdetail%252Fen%252Fip_21_6966%26a%3DEuropean%2BCommission&a=Europea n+Commission]

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M(TM) adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

The Novavax COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.

NVX-CoV2373 continues being evaluated in two pivotal Phase 3 trials.

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, NVX-CoV2373 achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine [https://c212.net/c/link/?t=0&l=en&o=3576637-1&h=3105155329&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3440781-1%26h%3D467849857%26u%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2116185%253Fquery%253Dfeatured_home%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine] (NEJM).

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of NVX-CoV2373 with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, NVX-CoV2373 achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.

PREVENT-19 is being conducted with support from the U.S. government, including the Department of Defense, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health at HHS. BARDA is providing up to $1.75 billion under a Department of Defense agreement (# MCDC2011-001).

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.

Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, has received conditional authorization from multiple regulatory authorities globally, including the European Commission and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide and will soon be under review in the U.S. for use in adults, adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating a COVID-seasonal influenza combination vaccine candidate in a Phase 1/2 clinical trial, which combines NVX-CoV2373 and NanoFlu*, its quadrivalent influenza investigational vaccine candidate, and is also evaluating an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. 

For more information, visit www.novavax.com [https://c212.net/c/link/?t=0&l=en&o=3576637-1&h=3106308365&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3460980-1%26h%3D3623927874%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3457869-1%2526h%253D982408174%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3440781-1%252526h%25253D3964594936%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3395501-1%25252526h%2525253D2463599076%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3392093-1%2525252526h%252525253D203886192%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3387216-1%252525252526h%25252525253D3917401194%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3260461-1%25252525252526h%2525252525253D2897486098%25252525252526u%2525252525253Dhttp%252525252525253A%252525252525252F%252525252525252Fwww.novavax.com%252525252525252F%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.novavax.com%2526a%253Dwww.novavax.com%26a%3Dwww.novavax.com&a=www.novavax.com] and connect with us on LinkedIn.

*NanoFlu identifies a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax. This investigational candidate was evaluated during a controlled phase 3 trial conducted during the 2019-2020 influenza season. 

Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, a COVID-seasonal influenza investigational combination vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for adolescents, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, and the efficacy, safety and intended utilization of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts: Investors Alex Delacroix | 240-268-2022 ir@novavax.com

Media Ali Chartan | 240-720-7804 media@novavax.com

Logo -

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Andere persberichten van deze organisatie

Damon Motors Selects EMQX--The World's Leading Solution for Cloud-Connected Vehicle Infrastructure

STOCKHOLM, June 28, 2022 /PRNewswire/ -- Damon Motors, makers of the high-performance, all-electric HyperDrive motorcycle powertrain and flagship HyperSport and HyperFighter models, has selected EMQX Enterprise for its forthcoming vehicle data infrastructure.

Intended to be the "smartest, safest, all-electric motorcycles on the planet," Damon's vehicles will use a cloud-connected AI engine and 360º advanced warning system to continually alert the rider to potential road hazards. The cloud data connection, built on the world's leading provider of IoT connection solutions, EMQX, provides a data messaging infrastructure to enable the motorcycle's onboard AI to improve its guidance over time.

"The EMQX solution is a critical piece of our infrastructure facilitating Motorcycle connectivity to the cloud, securely and at scale," said Rob Charter, Director of Engineering at Damon.

EMQX is a cloud-native Internet of Things (IoT) messaging platform that scales to 100 million concurrent device connections. Using open-source clustering technology and open standard IoT protocols like Message Queuing Telemetry Transport (MQTT). EMQX can securely move large amounts of data from IoT devices such as vehicle sensors to the cloud and reliably deliver control messages from the cloud back to devices.

Damon's CoPilot vehicle safety system collects road and ride data using an array of cameras, radar, and non-visual sensors. Its onboard neural network continuously scans for potential danger and alerts the rider through haptic feedback on the handlebar, integrated windscreen LEDs, front and rearview cameras, and long-range radar displays.

Using data collected from vehicles and environments around the world and shared through the EMQX platform, the CoPilot AI will be able to improve over time to deliver more meaningful interactions tuned to the individual rider's behaviors.

"What Damon Motors is doing with CoPilot is a huge leap forward for vehicle connectivity and rider safety," commented Dylan Kennedy, General Manager of EMQ Technologies. "It requires a fusion of precision sensing, edge computing, machine learning, and mobility, which is really impressive. The fact that we provide the data infrastructure with our best-in-class EMQX solution, helping to create a much safer environment for the motorcyclist, is very exciting and rewarding for EMQ."

EMQX also provides native integrations with many services and databases in the cloud for ease in distributing, processing, and analyzing vehicle telemetry data. The Internet of Vehicles is repeatedly turning to EMQ to provide solutions that decrease network latency and enable hyper scaling.

Damon's HyperSport and HyperFighter motorcycles are available for reservation now. The CoPilot cloud network is expected to go live in late 2022 with the first vehicles estimated to ship in early 2024.

About Damon Motors

https://damon.com

Damon Motors is a global technology leader disrupting urban mobility. Headquartered in Vancouver, Canada, Damon is leading the future of motorcycling with never-before-seen technologies. Starting with the HyperSport, Damon has reimagined the relationship between bike and rider--erasing the divide to make them one. Anchored by its proprietary electric powertrain, HyperDrive(TM), the company has stunned the motorcycling world by delivering earth-scorching speed, ferocious design, and epic new technologies like CoPilot(TM) and Shift(TM) that make motorcycling smarter, safer and cleaner. Damon continues to push limits to create a global impact and shift the perception of mobility and safety.

About EMQ

https://www.emqx.com

EMQ is an open-source IoT data infrastructure software provider, delivering the world's leading cloud-native MQTT-based IoT messaging platform and streaming database, providing a one-stop cloud-native solution for real-time IoT data connection, movement, processing and analytics, from edge to cloud to multicloud.

The flagship product EMQX is adopted by more than 10,000 enterprise users from over 50 countries, connecting more than 100 million IoT devices worldwide. Trusted by over 300 customers in business-critical production environments, EMQ powers future-proof IoT solutions and enterprise digital transformation.

Photo -

Logo -

CONTACT: Melanie Wu, +86-13918520943, melanie.wu@emqx.io

36 minuten geleden

Wemade's MMORPG masterpiece, MIR4, to reveal new PVP content - Bicheon Heist

-- New Clan PVP Content Revealed for MIR4! SEOUL, South Korea, June 28, 2022 /PRNewswire/ -- MIR4 [https://mir4global.com/]'s new PVP content, Bicheon Heist, will be revealed June 28, 2022.

"Defend the Darksteel or be Heisted!"

Adding new excitement to the MIR continent, Bicheon Heist will occur every Friday from 10pm to 11pm starting July 1. Bicheon Castle's underground Darksteel vault has been opened and the clan that rules over Bicheon Castle, together with their allies, must defend against the schemes of the Heisters who seek to plunder Darksteel from the vault. Top 20 clans in the server that are not allied with the Defenders are able to participate as Heisters.

If the Heisters destroy the Iron Gate blocking the entrance to the Darksteel vault and defeat the menacing Master Guardian 'Cheol Mujin' who guards the Darksteel, numerous Darksteel Boxes will be theirs for the taking. Additional rewards such as Legendary Treasure Pieces, Mystic Stones, and Darkened Stones containing materials required to craft Legendary-grade Spirit Treasures can also be obtained.

Exclusive missions for Expedition content have also been added. Players can experience more diverse missions across servers and will receive bountiful loot to help progress their characters as they complete these missions.

Dark Crown Prince Wooska, a new Legendary Wind Spirit will also be introduced through the update. This Legendary Wind Spirit is extremely tough and highly specialized in physical defense. To commemorate the release of the Dark Crown Prince Wooska, a Special Summon tab will become available until the July 26th update. When a Legendary Spirit is summoned through the Special Summon during this period, players will have a 100% chance of obtaining the new Spirit, Dark Crown Prince Wooska.

From my battle to our war! More information about MIR4 can be found on the official site.

Photo - Logo -

CONTACT: Yeonghyun Lee, +82-2-3709-2000, yeonghyun@wemade.com

48 minuten geleden

Betalingsbarometer Atradius: zakelijke wanbetalingen in Azië met 60 procent gestegen in vergelijking met 2021

-- Bedrijven Azië getroffen door verstoring wereldhandel -- Enorme toename afschrijvingen brengt liquiditeit in gevaar -- Nederlandse exporteurs moeten rekening houden met hogere betalingsrisico's AMSTERDAM, 28 juni 2022 /PRNewswire/ -- Het innen van onbetaalde zakelijke facturen bezorgt Aziatische bedrijven grote kopzorgen. Dit vraagstuk speelt zowel bij hun binnenlandse afnemers als bij afnemers uit exportmarkten in de regio. Het te laat of niet voldoen van betalingen zorgt voor een steeds grotere druk op de liquiditeit van deze bedrijven. Het risico op wanbetaling neemt daardoor ook toe voor Nederlandse bedrijven die naar Azië exporteren.

Voor de jaarlijkse Betalingsbarometer Azië heeft Atradius bedrijven ondervraagd in zeven Aziatische markten (China, Hongkong, India, Indonesië, Singapore, Taiwan en Vietnam) en in de Verenigde Arabische Emiraten. Hun grootste zorg zijn de wanbetalingen waar zij steeds vaker mee te maken hebben. Door uiterst onzekere economische omstandigheden zijn deze in vergelijking met de resultaten van 2021 toegenomen met maar liefst 60 procent.

"Azië is nog steeds een interessante markt voor Nederlandse exporteurs", aldus Rik Broekman, Head of Commercial van Atradius. "De onderzochte regio is goed voor bijna 7 procent van de Nederlandse goederenexport. De groei in Azië valt dit jaar terug naar 4,5 procent, om in 2023 weer iets te stijgen naar 5 procent. Veel bedrijven in de regio zijn echter wereldwijd actief en voelen de verstoringen in de wereldhandel die het gevolg zijn van de pandemie en geopolitieke spanningen. Daarnaast worstelt de maakeconomie met toenemende kosten van ruwe materialen, transport en brandstoffen. De stijging van het aantal wanbetalingen kan een signaal zijn dat het ondernemersklimaat onder grote druk staat."

50 procent van de uitstaande facturen in de regio wordt te laat betaald (tot 90 dagen na factuurdatum). Het probleem speelt nog sterker bij langdurig onbetaalde handelsschulden (meer dan 90 dagen) die als oninbaar moeten worden afgeschreven. De problemen zijn het grootst in Taiwan, dat kampt met een afschrijvingspercentage van 8 procent: bijna een verdriedubbeling ten opzichte van vorig jaar. In Hongkong en Singapore hebben bedrijven te maken met een gemiddelde stijging van 50 procent. In Indonesië namen de oninbare vorderingen toe met 40 procent. Vietnam is voor het eerst in de Betalingsbarometer van Atradius opgenomen. Bedrijven uit dit land geven aan dat hun liquiditeit steeds meer onder druk staat door zowel afschrijvingen (6 procent van de totale waarde van zakelijke facturen) als onbetaalde handelsschulden, die ongeveer de helft van de waarde van de zakelijke handel vertegenwoordigden.

"De uitkomsten van de Betalingsbarometer Azië zijn verontrustend", vervolgt Broekman. "Gezien de aanhoudende onzekerheid in de markt verwachten we niet dat de trend van dubieuze vorderingen zich snel zal herstellen. Nederlandse exporteurs doen er dan ook goed aan om heldere betalingsafspraken met hun afnemers in de regio Azië te maken."

De Atradius Betalingsbarometer 2022 voor Azië kan worden gedownload van www.atradius.nl (sectie Publicaties). Het onderzoek biedt een diepgaande analyse van hoe bedrijven in belangrijke markten in Azië omgaan met risico's op wanbetaling bij verkopen op krediet aan zakelijke klanten. Onderwerpen die aan bod komen, zijn onder meer betalingstermijnen, de tijd die nodig is om facturen te innen, het beheer van betalingsachterstanden, de gevolgen van betalingsachterstanden voor bedrijven en verwachte zakelijke trends.

Over Atradius Atradius biedt wereldwijd kredietverzekeringen, borgstellingen en garanties, incasso en informatiediensten aan via strategische aanwezigheid in meer dan 50 landen. De producten van Atradius beschermen bedrijven over de hele wereld tegen betalingsrisico's die verbonden zijn aan de verkoop van producten en diensten op krediet. Atradius maakt deel uit van Grupo Catalana Occidente (GCO.MC), een van de grootste verzekeraars in Spanje en een van de grootste kredietverzekeraars ter wereld.

Voor meer informatie www.atradius.nl Twitter | LinkedIn | YouTube

Logo -

CONTACT: Noot aan de redactie (niet voor publicatie): Atradius, Corporate Communications & Marketing, Mariëlla Dalstra-van Emst, Tel. +31 (0)20 553 2394, Mob. +31 (0)6 1297 8985, E-mail: mariella.dalstra@atradius.com

4 uur geleden

Vodafone Germany Chooses RealNetworks to Test an Anti-Fraud Voice Call Solution Using KONTXT

Pilot project will gain insights on spam rejection performance and customer experience

SEATTLE, June 27, 2022 /PRNewswire/ -- RealNetworks(®) , a leader in AI-powered digital media software and services, today announced a pilot program with Vodafone Germany to launch a new service called Vodafone CallProtect. Vodafone CallProtect will warn Vodafone Germany customers of potential fraudulent, scam, or spam-type calls. The technology behind CallProtect is RealNetworks' KONTXT(®), an AI-based anti-spam solution for messaging and voice calls, which includes the KONTXT Reputation Service database.

The benefit of RealNetworks technology is the offering of a rich feature set for anti-fraud protection for both voice calls and messaging. Clients of KONTXT decide which modules are activated for data analysis and customer protection. The Vodafone CallProtect pilot project will use the KONTXT Android SDK for call enrichment and the KONTXT Reputation Service for number lookups. The KONTXT Reputation Service database contains known spam numbers provided from leading spam database providers. The Reputation Service is also capable of MSISDN risk rating based on the latest AI/ML technology.

Vodafone CallProtect will be integrated into the Vodafone Secure Net service for Android. Vodafone Secure Net is a mobile network-based security product that helps protect Vodafone customers' mobile devices. When connected to the Vodafone mobile network in Germany, it automatically blocks harmful sites and quickly protects against viruses before they can cause harm. Secure Net users will be able to activate and deactivate the service. Once activated, all incoming calls will be matched against a database to verify if the calling number is a known spam or scam number. If a positive match is detected, an informational message is displayed on the user's phone allowing them to reject the call.

"Global fraudulent call activities increased substantially since the outbreak of the pandemic, which led to the launch of this initiative," said Mathias Grünwald, Director Sales at RealNetworks. "We are excited about Vodafone's decision to partner with RealNetworks to take advantage of our leading anti-fraud solution KONTXT to protect their customers".

CallProtect will be provided for free to existing Vodafone Secure Net users in Germany. The pilot project will be active for six months starting from the launch of the CallProtect service. The goal of the pilot is to gain insights about user acceptance and assess the performance of the service.

About RealNetworks' KONTXT Building on a rich history of digital media expertise and innovation, RealNetworks(®) has created a new generation of products that employ best-in-class artificial intelligence and machine learning to enhance and secure our daily lives. KONTXT(®) (kontxt.com) is an industry-leading NLP (Natural Language Processing) platform for categorizing and blocking spam and fraudulent text messages, images, and voice calls, to help carriers build customer loyalty and drive new revenue through text message classification and antispam. For more information, visit: [https://c212.net/c/link/?t=0&l=en&o=3577608-1&h=3341943303&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3106777-1%26h%3D1209772609%26u%3Dhttp%253A%252F%252Fwww.realnetworks.com%252F%26a%3D%25C2%25A0&a=%C2%A0]realnetworks.com.

Media Contact:   Deena Rataezyk drataezyk@realnetworks.com 425-373-6100

KONTXT - KONTXT(TM) helps you defeat fraud and improve customer engagement in real-time.

Logo-

9 uur geleden

NEOM and McLaren Racing announce strategic title partnership to drive innovation and talent development in electric motorsport

-- NEOM and McLaren Racing will come together as 'NEOM McLaren Electric Racing' to compete across Formula E and Extreme E, driving innovation at the forefront of sustainable motorsport. -- McLaren Racing will become a founding tenant in the Research and Innovation Campus of OXAGON, NEOM's home to advanced and clean industries. NEOM, Saudi Arabia, June 27, 2022 /PRNewswire/ -- NEOM announced today a strategic partnership with McLaren Racing to become the title partner of the McLaren Formula E and Extreme E racing teams, bringing two all-electric race series' together for the first time under the banner of 'NEOM McLaren Electric Racing'.

Commenting on the partnership, Nadhmi Al-Nasr, CEO of NEOM, said: "Our partnership with McLaren Racing complements NEOM's commitment to driving sustainable solutions and tackling some of society's most pressing challenges. The partnership will allow us to share our collective resources and experience to yield exciting results, not only for our own organizations, but also for the broader automotive and sports industries. NEOM is an economic engine for the Kingdom of Saudi Arabia and will be a hub for innovative businesses like McLaren Racing to conduct cross-industry research, incubate, collaborate and bring new technologies to the world."

McLaren will collaborate with NEOM across multiple areas, becoming a founding partner of OXAGON, a city in NEOM set to be a blueprint for the future of advanced and clean industries and a hub for innovation. McLaren will be located within OXAGON's Research and Innovation Campus, which is being designed by international architects, Grimshaw. The campus will provide cutting edge facilities and collaboration spaces, accelerating ideas from labs to market to develop industries and products of the future.

Zak Brown, CEO of McLaren Racing, said: "We are delighted to welcome NEOM to the McLaren Racing family. This is an incredible way to kick off our entry into Formula E and to unify our electric racing series. We are thrilled to introduce NEOM McLaren Electric Racing and to work with NEOM to nurture talent and drive innovation. Working with OXAGON will allow us to make meaningful contributions through our Accelerator program and assist with the development of advanced and clean industries."

Additionally, through its bespoke Accelerator program, where performance-driven data can be translated into the culture and thinking of its partners, McLaren will lend its digital and analytical expertise as a technical partner of OXAGON's advanced and clean manufacturing ecosystem.

A further significant element to the partnership will be rolled out during 2023 when, in line with NEOM's commitment to developing Saudi talent, McLaren and NEOM will create a bespoke program to nurture engineers and students; Twenty Saudi graduates from NEOM's Graduate Program will each take part in a one-year placement with McLaren Racing at the McLaren Technology Center in the United Kingdom. Entitled 'The McLaren Way," this performance and development program will help unlock the performance and potential of all NEOM teams through a range of initiatives.

The partnership is part of NEOM's continued commitment to sustainable goals within motorsport across both Formula E and Extreme E, with both race formats competing in exhilarating racing across the globe. Building on the success of NEOM's Mercedes-EQ Formula E principle partners relationship, NEOM McLaren Formula E Team will be formed through the acquisition of the Mercedes-EQ Formula E Team, expected to complete later this year, which will see the reigning champion team become part of the McLaren racing family.

NEOM was also the location for Extreme E's second-season inaugural race which took place in February of this year. The race helped to raise awareness of the challenges faced by climate change as well as the need to continue developing sustainable motorsport technologies within the region.

The Kingdom of Saudi Arabia has invested significantly in motorsport platforms in recent years, with the Ministry of Sport signing agreements to host Formula E, Extreme E, Formula One and the Dakar Rally.

About NEOM

NEOM is an accelerator of human progress and a vision of what a New Future might look like. It is a region in northwest Saudi Arabia on the Red Sea being built from the ground up as a living laboratory - a place where entrepreneurship will chart the course for this New Future. It will be a destination and a home for people who dream big and want to be part of building a new model for exceptional livability, creating thriving businesses and reinventing environmental conservation.

NEOM will include hyperconnected, cognitive towns and cities, ports and enterprise zones, research centers, sports and entertainment venues, and tourist destinations. As a hub for innovation, entrepreneurs, business leaders and companies will come to research, incubate and commercialize new technologies and enterprises in groundbreaking ways. Residents of NEOM will embody an international ethos and embrace a culture of exploration, risk-taking and diversity.

For further information email media@neom.co [mailto:media@neom.co]m or visit www.neom.com and www.neom.com/en-us/newsroom

About McLaren Racing

McLaren Racing was founded by New Zealand racing driver Bruce McLaren in 1963. The team entered its first Formula 1 race in 1966, since then McLaren has won 20 Formula 1 world championships, more than 180 Formula 1 grands prix, the Indianapolis 500 three times, and the Le Mans 24 Hours at its first attempt.

The team competes in the FIA Formula 1 World Championship with Lando Norris and Daniel Ricciardo, the NTT INDYCAR Series with Arrow McLaren SP drivers Pato O'Ward and Felix Rosenqvist, and the Extreme E Championship with Emma Gilmour and Tanner Foust. McLaren will compete in Season Nine of the FIA Formula E World Championship in 2022/23.

McLaren was the first F1 team to be awarded the Carbon Trust Standard in 2010 and has retained it since on a bi-annual basis, most recently in February 2021. The team was also the first in F1 to be given the FIA Sustainability Accreditation Award at a three-star level in 2013 as part of the FIA Environmental Certification framework, before becoming a signatory to the UN Sports for Climate Action Commitment in 2021.

This material is distributed by Teneo Strategy LLC on behalf of NEOM Company. Additional information is available at the Department of Justice, Washington, DC.

Photo -

CONTACT: Hussein Itani: +971 56 334 6909 | John Greenway: john.greenway@teneo.com, +971 58 565 0626

12 uur geleden

After becoming World Natural Heritage Site for 15 years, Chongqing's Wulong aims for global tourism destination in latest entrepreneurial attempt

CHONGQING, China, June 27, 2022 /PRNewswire/ -- In order to continuously leverage the brand value of the World Natural Heritage Site and better build an exchange bridge to introduce Wulong to the world, a conference to celebrate the 15th anniversary of the Wulong Karst's successful inclusion into the World Natural Heritage List was held in Wulong District, southwest China's Chongqing. The conference focuses on the strict protection, continuous inheritance and sustainable utilization of the precious site, according to the Publicity Department of Wulong District, Chongqing Municipality.

Wulong, located in the lower reaches of Wujiang River in the southeast of Chongqing, enjoys convenient transportation such as roads, railways, waterways and civil airports.

In 1994, marked by the opening of Furong Cave to the public, Wulong tourism started to grow. In 2007, the Wulong Karst became the first World Natural Heritage Site in Chongqing. In 2015, it was honored as a model city in sustainable development by the United Nations. In 2008, Wulong started its second entrepreneurial attempt in tourism with the main goal of increasing the total number of tourists and strengthening the tourism economy. At present, Wulong District is a World Natural Heritage Site, a national tourism resort, and a national 5A tourist attraction, among others.

"Wulong has stayed firm in leveraging the natural heritage to empower tourism industry, which provides a local example of transforming and utilizing natural heritage value to improve people's livelihood," a senior official of Wulong District said.

Wulong received 40.7 million visits in 2021, 20 times that of 2008, while the overall tourism income reached 19.73 billion yuan, 19.6 times that of 2008. The sustainable development of tourism industry in Wulong has brought great economic, social and ecological benefits, forming a good circular interaction with natural heritage protection.

Yuan Daoxian, an academician with the Chinese Academy of Sciences, said that in the past 15 years, Wulong has undergone sea changes, with impressive social, economic and cultural achievements. These are closely related to the successful inclusion into the World Natural Heritage List and Wulong's efforts in heritage protection and management.

With the stratification and individuation of tourism consumption demand and the specialization and sophistication of tourism development model, tourism industry has undergone all-round and comprehensive changes. In order to effectively respond to new challenges, in February this year, Wulong District launched the third entrepreneurial attempt in developing local tourism, which focused on going global. The local government has decided to speed up the development of Wulong into a world-renowned tourism destination and a green development innovation demonstration area.

Wulong has developed a plan to help local tourism go global, with 165 cultural tourism projects totaling 140.6 billion yuan in investment value. The plan proposed to build six industrial chains, including research, sports, art, health care, marriage and services, and promote the deep integration of tourism with industry, agriculture, construction and modern services.

The latest tourism development campaign no long just seeks to increase the number of tourists, but to improve the tourism quality and efficiency, so as to achieve common prosperity driven by tourism. Since the implementation, the campaign has achieved noticeable results. From January to May this year, Wulong received 14.85 million visits, up 11.5 percent year on year, and its overall tourism income reached 6.53 billion yuan, up 12.7 percent year on year.

Since the successful inclusion into the World Natural Heritage List, Wulong has made great efforts to make the natural heritage a global fame. The Furong Cave has formed a sister park with the Mammoth Cave in the United States and the Clamouse Cave in France. The Fairy Mountain signed a contract with Swiss Jungfrau and successfully held international and domestic academic conferences such as the 14th national cave academic conference. Wulong has established friendly and cooperative relations with six cities and regions, including Switzerland's Grindelwald and Italy's Subiaco, and expanded the circle of friends of international friendship cities. The popularity and influence of Wulong's karst world natural heritage are constantly expanding.

CONTACT: Ms. Fu, Tel: +86-10-63074558

14 uur geleden